While Kawasaki disease (KD) typically affects children, it can, in rare cases, affect adults, leading to coronary artery abnormalities and acquired heart disease. Given that the disease is rare in adults and that its etiology is not fully understood, diagnosis and treatment of KD in adults can be challenging.
While Kawasaki disease (KD) typically affects children, it can, in rare cases, affect adults, leading to coronary artery abnormalities and acquired heart disease. Given that the disease is rare in adults and that its etiology is not fully understood, diagnosis and treatment of KD in adults can be challenging.
Some small studies of KD in children have demonstrated that infliximab can be used as a treatment for KD that is refractory to conventional treatment and that, in children, the therapy is well tolerated. Now, a recent case report describes a case of adult-onset KD that was refractory to high-dose intravenous immunoglobulin (IVIG) but responded well to infliximab therapy.
The report describes a 24-year-old man who developed fever, diarrhea, and erythema of his lower limbs. As infection was suspected, he was given intravenous antibiotics, but they failed to benefit him, and his temperature remained elevated. After 10 days, the patient had shortness of breath, and a chest x-ray showed a 52% chest-thoracic ratio and bilateral pulmonary congestion. An electrocardiogram showed widespread ST elevations, and a transthoracic echocardiogram revealed decreased diffuse left ventricular wall motion and pericardial effusion. On day 11, he experienced peeling skin on the fingertips and arthralgia of the shoulders and wrist. On day 17, the echocardiogram showed dilation at the proximal sites of the right coronary artery and left descending artery.
Given that the patient met most of the criteria for adult-onset KD, he was diagnosed with the disease and treated with high-dose IVIG and acetylsalicylic acid on days 18 and 19. He did not respond adequately to these treatments, and his fever and arthralgia did not improve.
On day 21, the patient was given infliximab at a dose of 5 mg/kg as a single intravenous infusion. The next day, his fever resolved, and his arthralgia improved. On day 30, the patient was discharged without symptoms.
The authors of the case report conclude that, while rare, KD should be included in the differential diagnosis of an adult patients with unexplained fever, mucocutaneous changes, lymphadenopathy, and congestive heart failure. Additionally, they say, infliximab can be an effective therapy for refractory adult-onset KD.
Reference
Kawaguschi T, Rikitake Y, Tsuruda T, et al. Infliximab as an alternative therapy for refractory adult onset Kawasaki disease: a case report. Medicine (Baltimore). 2018;97(40):e12720. doi: 10.1097/MD.0000000000012720.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.